Clinical Scorecard: Melan-Dx: An Enhanced Vision-Language Framework for Improved Differential Diagnosis of Melanocytic Neoplasms

At a Glance

Key Highlights

• Melan-Dx integrates a curated multi-modal dataset of 2893 images and 1102 expert-annotated knowledge entries to augment pathology vision-language models.
• Demonstrates significant diagnostic accuracy improvements: up to 13.8% over linear and fully finetuned methods, and 23–70.6% over zero-shot approaches.
• Achieves high performance metrics including 0.869 accuracy for binary classification and 0.699 Top-1 accuracy for forty-class classification of melanocytic neoplasms.

Guideline-Based Recommendations

Diagnosis

• Utilize multi-modal AI frameworks like Melan-Dx to support differential diagnosis of melanocytic neoplasms across numerous histologic subtypes.
• Incorporate curated expert knowledge databases to enhance interpretation of pathology images without requiring fine-tuning of vision backbones.

Management

• Leverage AI-assisted diagnostic tools to reduce misdiagnosis and improve early and accurate identification of melanoma and related neoplasms.

Monitoring & Follow-up

• Continuously validate AI model performance across patch-level and whole-slide image analyses to ensure diagnostic reliability.

Risks

• Be aware of potential diagnostic errors and overdiagnosis in melanoma; AI tools should complement, not replace, expert clinical judgment.

Patient & Prescribing Data

Patients undergoing histopathologic evaluation for suspected melanocytic neoplasms

Improved diagnostic accuracy with Melan-Dx may facilitate timely and appropriate management decisions, potentially impacting prognosis.

Clinical Best Practices

• Integrate AI frameworks like Melan-Dx as adjunct diagnostic support in dermatopathology workflows.
• Maintain expert oversight and validation of AI-generated differential diagnoses to mitigate errors.
• Request access to proprietary image and knowledge databases under appropriate agreements to enhance institutional diagnostic capabilities.

References

• American Cancer Society. Cancer facts and figures 2024
• Naik, P. P. Cutaneous malignant melanoma: a review of early diagnosis and management. World J. Oncol. 12, 7 (2021)
• Liersch, J., von Köckritz, A. & Schaller, J. Dermatopathology 101. Part 2–skin tumors. J. Dtsch. Dermatol. Ges. 15, 906–929 (2017)
• Graber, M. L. The incidence of diagnostic error in medicine. BMJ Qual. Saf. 22, ii21–ii27 (2013)
• Adamson, A. S., Naik, G., Jones, M. A. & Bell, K. J. Ecological study estimating melanoma overdiagnosis in the USA using the lifetime risk method. BMJ Evid. Based Med. 29, 156–161 (2024)
• Sondermann, W. et al. Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis. Medicine 95, e4332 (2016)
• Kutzner, H. et al. Overdiagnosis of melanoma–causes, consequences and solutions. J. Dtsch. Dermatol. Ges. 18, 1236–1243 (2020)
• Venkatesh, K. P., Raza, M. M., Nickel, G., Wang, S. & Kvedar, J. C. Deep learning models across the range of skin disease. NPJ Digit. Med. 7, 32 (2024)
• Venkatesh, K., Raza, M. & Kvedar, J. AI-based skin cancer detection: the balance between access and overutilization. NPJ Digit. Med 6, 147 (2023)
• Marwaha, J. S. & Kvedar, J. C. Crossing the chasm from model performance to clinical impact: the need to improve implementation and evaluation of AI. NPJ Digit. Med. 5, 25 (2022)